Adalimumab (Humira®) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade®) or etanercept (Enbrel®): results from the STURE registry at Karolinska University Hospital

Author: Wick M. C.   Ernestam S.   Lindblad S.   Bratt J.   Klareskog L.   van Vollenhoven R. F.  

Publisher: Informa Healthcare

ISSN: 0300-9742

Source: Scandinavian Journal of Rheumatology, Vol.34, Iss.5, 2005-10, pp. : 353-358

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content